Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Bibliographic Details
Title:	Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Authors:	Loong, Herbert, Brunello, Antonella, Krieg, Andreas, Algulnik, Mark, Riedel, Richard, Okuno, Scott, Loggers, Elizabeth, Alcindor, Thierry, Ferraresi, Virginia, Serrano, César, Randall, R. Lor, Wilky, Breelyn, Ravi, Vinod, Gelderblom, Hans ^{a, , }, Bhadri, Vivek ^b, Stacchiotti, Silvia ^c, Bauer, Sebastian ^{d, e}, Wagner, Andrew J ^f, van de Sande, Michiel ^a, Bernthal, Nicholas M ^g, López Pousa, Antonio ^h, Razak, Albiruni Abdul ⁱ, Italiano, Antoine ^{j, k}, Ahmed, Mahbubl ^l, Le Cesne, Axel ^m, Tinoco, Gabriel ⁿ, Boye, Kjetil ^o, Martín-Broto, Javier ^p, Palmerini, Emanuela ^q, Tafuto, Salvatore ^r, Pratap, Sarah ^s, Powers, Benjamin C ^t, Reichardt, Peter ^u, Casado Herráez, Antonio ^v, Rutkowski, Piotr ^w, Tait, Christopher ^x, Zarins, Fiona ^x, Harrow, Brooke ^x, Sharma, Maitreyi G ^x, Ruiz-Soto, Rodrigo ^x, Sherman, Matthew L ^x, Blay, Jean-Yves ^y, Tap, William D ^{z, aa, *}
Source:	In The Lancet 22-28 June 2024 403(10445):2709-2719
Database:	ScienceDirect